Comparison of the effect of Healon, Healon GV, Healon 5, Viscoat, and Ocucoat on platelet aggregation under in vitro conditions.
OBJECTIVE
To study the effect of Healon, Healon GV, Healon 5, Viscoat, and OcuCoat on platelet aggregation under in vitro conditions.


METHODS
Ocular viscoelastic devices including Healon, Healon GV, Healon 5, Viscoat, and OcuCoat were studied to investigate the effect of these agents on platelet aggregation under in vitro conditions. The experiments were performed by using platelet-rich plasma with an aggregometer. Aggregation was induced with three different agonists including 5''-adeno-sinediphosphate (ADP), epinephrine (EPI), and collagen (Col ). The results were obtained as a percentage of maximal aggregation and compared with controls using one-way analysis of variance (ANOVA) test.


RESULTS
The tests with ADP as aggregating agent revealed that the percentages of maximal aggregation were a mean of 75 +/- 4.35% for ADP only, 67 +/- 4.35% for Healon, 59.33 +/- 3.51% for Healon GV, 70 +/- 3% for Healon 5, 58 +/- 3.46% for Viscoat, and 64 +/- 2% for OcuCoat. Kruskal-Wallis one-way ANOVA test revealed no significant decrease in the percentage of maximal aggregation for all tested substances. With EPI, aggregation was induced in all control samples with a mean of 80.66 +/- 2.08%. The mean percentage of maximal aggregation was 67 +/- 3% for Healon, 77.66 +/- 4.04% for Healon GV, 77 +/- 4% for Healon 5, 80.6 +/- 4.04% for Viscoat, and 65 +/- 5% for OcuCoat. Statistical analysis showed no significant difference. With collagen, maximum aggregation was 74 +/- 5.29% for controls, 65 +/- 4.35% for Healon, 54 +/- 2% for Healon GV, 51 +/- 2.64% for Healon 5, 59 +/- 2% for Viscoat, and 72.66 +/- 1.52% for OcuCoat. Kruskal -Wallis one-way ANOVA test revealed no significant change in the percentage of maximal aggregation for all tested substances in the experiments.


CONCLUSIONS
Ophthalmic viscosurgical devices like Healon, Healon GV, Healon 5, and Viscoat that contain glycosaminoglycans and OcuCoat that contains hydroxypropyl methylcellulose have inhibitory effects on platelet aggregation but the effect is not statistically significant and there is no difference among the ocular viscoelastic devices in regard to inhibitory effect on platelet aggregation.
Aras
C
C
Department of Ophthalmology, Istanbul University, Istanbul, Turkey. carasmd@gmail.com
Baslar
Z
Z
Unal
M
M
Horoz
H
H
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D002807:Chondroitin / Q000494:pharmacology*; D002809:Chondroitin Sulfates; D003094:Collagen / Q000494:pharmacology; D004338:Drug Combinations; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology*; D065347:Hypromellose Derivatives; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives* / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*
D004338:Drug Combinations; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D065347:Hypromellose Derivatives; D000244:Adenosine Diphosphate; D006820:Hyaluronic Acid; D008747:Methylcellulose; D002807:Chondroitin; D002809:Chondroitin Sulfates; D003094:Collagen; D004837:Epinephrine